28bio
Innovation Partner
28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today’s neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition.
HUB Organoids
Event Partner
HUB Organoids, part of the Life Science Business of Merck KGaA, Darmstadt, Germany, specializes in the application of Organoid Technology to drug discovery, personalized medicine, and disease modeling. Founded in 2013 following the discovery of adult stem cells, HUB´s drug development platform uses advanced 3D organoid models derived from patient tissues, enabling more accurate and predictive research for preclinical testing and therapeutic development. HUB´s innovative platform accelerates the discovery of effective treatments by closely mimicking human biology and is available on a fee-for-service basis to scientists working in drug discovery and development in the therapeutic areas of oncology, inflammation/IBD, infectious diseases, and for toxicology investigation.
